Nuclear transcription factor NF-kB content in the serum of patients with secondary edematous breast cancer
Білий О.М.1, Мітряєва Н.А.2, Красносельський М.В.1, Гребіник Л.В.2
- 1Kharkiv National University by V.N. Karazin
- 2SU «Institute for Medical Radiology and Oncology by S.P. Grigoriev of National Academy of Medical Sciences of Ukraine», Kharkiv
Summary. Nuclear transcription factor NF-kappa-B (NF-kB) is one of the most universal cellular regulators that play an important role in cell proliferation, apoptosis, inflammation, because it regulates the expression of genes involved in these processes. Regulation of NF-kB signaling pathways is impaired in many human tumors, including breast cancer (BC). The combination of oncological and inflammatory processes accompanied by NF-kB activation makes it important to study this factor in the case of an aggressive form — secondary edematous breast cancer (SEBC), the pathogenesis of which is associated with carcinogenesis and the development of inflammatory processes. Objective. To study the content of NF-kB factor in the serum of SEBC patients, analysis of the relationship of this indicator with ER and Her2/neu-status of the tumor and the main clinical and morphological features of the disease. Materials and methods. In 42 patients with SEBC and 45 patients with BC without edema, the content of the NF-kB1 subunit (p105 → p50) in the blood serum was determined by enzyme-linked immunosorbent assay. Expression of ER and Her2/neu was determined by immunohistochemical method in the tumor according to conventional methods using 3.76) and in 69 monoclonal antibodies. Results. The factor NF-kB was detected before treatment in 86% of patients with SEBC (Me=% of people with BC without edema (Me=1.79). The level of the factor was higher in SEBC group in 2,1 times. It was found that in patients with SEBC NF-kB content in the group ER(–) higher than in the group ER(+), as well as higher in the group Her-2/neu(+), compared with the group Her-2/neu(–), which confirms its relationship with tumor aggressiveness. The highest values of NF-kB were found in patients with SEBC with ER- + Her-2/neu(+) tumor phenotype (median 17.5 ng/ml). No significant relationship of NF-kB with age, menopausal status, lymph node involvement, tumor differentiation, tumor size in HPLC was not found. Conclusions. Based on the obtained results, hypersecretion of NF-kB factor is shown in most patients with SEBC, which indicates a high carcinogenic potential of the tumor and the presence of an inflammatory component. In view of the above, it can be considered appropriate for SEBC to determine NF-kB for additional characterization of the aggressiveness of the tumor process and individualization of treatment.
Leave a comment